In silico Studies on the Interaction Between Bioactive Ligands and DPPIV: Insights on Potential Candidates for the Treatment of type 2 Diabetes Mellitus

Author(s): Michelle C.M.R. Martins, Simone Q. Pantaleao, Michell de Oliveira Almeida, Karen C. Weber, Kathia M. Honorio*

Journal Name: Medicinal Chemistry

Volume 17 , Issue 3 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Introduction: The enzyme called dipeptidyl peptidase IV (DPP-IV) is related to the glycemic control associated with the stimulation of the pancreas to produce insulin. So, its inhibition is a good strategy for the treatment of type 2 diabetes mellitus.

Methods: In this study, we have employed molecular modeling strategies such as CoMFA, molecular docking, molecular dynamics, and binding free energy calculations of a set of DPP-IV inhibitors in order to understand the main characteristics related to the biological activity of these ligands against the enzyme.

Results: The models obtained from CoMFA presented significant values of internal (0.768) and external (0.988) validations. Important interactions with some residues, such as Glu205, Tyr666, Arg125, Ser630, Phe357 and Tyr662, were also identified. In addition, calculations of the electronic properties allowed relating the LUMO and HOMO energies with the biological activity of the compounds studied. The results obtained from the molecular dynamics simulations and the SIE calculations (ΔG) indicated that the inhibitor 40 increases the stability of the DPP-IV target.

Conclusions: Therefore, from this study, it is possible to propose molecular modifications of these DPP-IV inhibitors in order to improve their potential to treat type 2 diabetes.

Keywords: Diabetes, DPP-IV, inhibitors, docking, CoMFA, molecular dynamics, binding free energy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 29 January, 2020
Page: [247 - 263]
Pages: 17
DOI: 10.2174/1573406416666200129151256
Price: $65

Article Metrics

PDF: 20